tbuckley/cabot-search huggingface dataset:
Convulsions in Childhood
Authors: G. D. Read
Journal: BMJ (1950)

_~~~~~~~~~~~~~~~~~~~~~~~~~~MIA JOURNA in the Purkinje cells, they fit well with the clinical signs and provide an explanation for the respiratory failure which was the immediate cause of the patient's death.It is impossible to be certain whether this case should be regarded as one of acute idiopathic porphyria or whether it was toxic in origin, as we were unable to obtain enough urine for the porphyrin to be typed.Of the drugs which she received, the sulphadiazine would have been the most likely cause of her condition; Dobriner and Rhoads (1940) mention both clinical and experimental evidence that sulphonamides may cause increased excretion of porphyrins, and sulphadimidine (sulphamezathine) was one of the drugs administered in the fatal case reported by Abrahams et al.The difficulty remains that in all reported cases of toxic porphyria the predominant excretion product has been coproporphyrin.In our case symptoms, though slight at first, preceded sulphadiazine administration.The balance of evidence therefore seems to us to be in favour of this being an acute idiopathic porphyria rather than a toxic one.The urinary findings and the rapidly progressive neurological picture would also make this the more likely diagnosis.
Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
Authors: Tapan M. Kadia, Jorge E. Cortes, Marina Y Konopleva, Gautam M. Borthakur, Naveen Pemmaraju, Naval G. Daver, Guillermo Montalban Bravo, Ghayas C. Issa, Kiran Naqvi, Nicholas J. Short, Courtney D. DiNardo, Kapil N. Bhalla, Elias Jabbour, Koichi Takahashi, Koji Sasaki, Steven M. Kornblau, Rashmi Malla, Sherry A. Pierce, Xuemei Wang, Zeev E. Estrov, Michael Andreeff, Guillermo Garcia-Manero, Farhad Ravandi, Hagop M. Kantarjian
Journal: Blood (2019)
Neurogenesis and prolongevity signaling in young germ-free mice transplanted with the gut microbiota of old mice
Authors: Parag Kundu, Hae Ung Lee, Isabel Garcia-Perez, Emmy Xue Yun Tay, Hyejin Kim, Llanto Elma Faylon, Katherine A. Martin, Rikky Purbojati, Daniela I. Drautz-Moses, Sujoy Ghosh, Jeremy K. Nicholson, Stephan Schuster, Elaine Holmes, Sven Pettersson
Journal: Science Translational Medicine (2019)

The gut microbiota evolves as the host ages, yet the effects of these microbial changes on host physiology and energy homeostasis are poorly understood. To investigate these potential effects, we transplanted the gut microbiota of old or young mice into young germ-free recipient mice. Both groups showed similar weight gain and skeletal muscle mass, but germ-free mice receiving a gut microbiota transplant from old donor mice unexpectedly showed increased neurogenesis in the hippocampus of the brain and increased intestinal growth. Metagenomic analysis revealed age-sensitive enrichment in butyrate-producing microbes in young germ-free mice transplanted with the gut microbiota of old donor mice. The higher concentration of gut microbiota-derived butyrate in these young transplanted mice was associated with an increase in the pleiotropic and prolongevity hormone fibroblast growth factor 21 (FGF21). An increase in FGF21 correlated with increased AMPK and SIRT-1 activation and reduced mTOR signaling. Young germ-free mice treated with exogenous sodium butyrate recapitulated the prolongevity phenotype observed in young germ-free mice receiving a gut microbiota transplant from old donor mice. These results suggest that gut microbiota transplants from aged hosts conferred beneficial effects in responsive young recipients.
Pain in Phantom Limbs
Authors: L. Gillis
Journal: BMJ (1948)

~~~~~~~~~~~~~~~~~~~~~~~~~MFDICAL J OURNAL potent cause," the ebb and flow of inflammation, will be found ade.quate to explain the symptoms without the interposition of direct motor causes.Moreover, he will no longer fear the Greeks, even when bearing a question about pain-relief from haemorrhage, for he will be able to discard " muscular atonx from acute anaemia" as an unsatisfactory explanation, either in peptic ulcer or congestive dysmenorrhoea.Such prostration, as is implied, does not necessarily accompany pain-relief.Finally, if he leaves out the myogenic middle term, he will not be called upon to explain how nebulous motor disturbances can directly cause pain in ulcer patients, while definite and violent motor disturbances fail to cause pain in obstructive or regurgitant vomiting after gastro-enterostomy, or in obstruction at the duodeno-jejunal flexure due to carcinoma.Nor will he be asked to explain why, in pyloric obstruction, "the very powerful peristaltic waves which can be seeP through the abdominal wall are rarely accompanied by any discomfort" (Hurst and Stewart).-Iam, etc..
SCIDOT-39. K16ApoE ENHANCES Aβ-ASSOCIATED 11C-PiB DEPOSITION AND PET SIGNAL IN APP/PS1 TRANSGENIC MICE
Authors: Desmond Brown, Gobinda Sarkar, Teresa Decklever, Geoffry Curran, Ameet Sarkar, Ann Schmeichel, Suresh Swaminathan, Karunya Kandimala, Robert Jenkins, Terry Burns, Val Lowe
Journal: Neuro-Oncology (2019)

Abstract OBJECTIVE The K16ApoE peptide enhances delivery of multiple agents across the blood-brain barrier (BBB). Transgenic mouse models are central to elucidating the underlying pathophysiology of Alzheimer’s Disease (AD) and provide a system for evaluating novel therapeutic strategies. PET imaging plays a central clinical role in diagnosing human cases of AD but has had variable performance in mouse models. We investigated the role of K16ApoE to enhance delivery of a radiolabeled PET imaging tracer, 11C-PiB and assess whether this corresponds to improved PET sensitivity in APP/PS1 transgenic mice. METHODS Brain-delivery of 11C-PiB was accomplished by successive injections of K16ApoE and 11C-PiB. Distribution of 11C-PiB to the brain and heart was quantified via dynamic PET/CT imaging and digital autoradiography. RESULTS K16ApoE increased the brain uptake of 11C-PiB in both wild-type (WT) and APP/PS1 mice. Administration of K16ApoE increased the PET standard uptake value of 11C-PiB at 5 minutes in WT mice from 1.132 to 2.963 (p=0.006) and in APP/PS1 mice from 0.842 to 3.268 (p=0.016). Enhancement peaked at 5 minutes. Binding was reversible with similarly increased kinetics in both WT and APP/PS1 mice. The absolute values were higher in APP/PS1 mice suggesting increased retention. The increased retention in APP/PS1 mice was consistent with specific binding to A-beta plaques as unlabeled PiB reduced 11C-PiB signal retention. CONCLUSION K16ApoE mediates enhancement of 11C-PiB signal in APP/PS1 mice brains with increased PET sensitivity. There is increased uptake kinetics in both WT and APP/PS1 mice with specific A-beta plaque binding in the latter. This enhanced delivery of the PET tracer has implications for development and testing of new hypotheses and the efficacy of novel therapeutic paradigms. K16ApoE has potential for improving delivery of several agents across the BBB. This has implication for delivery of diagnostic and therapeutic agents for neurodegenerative and neuro-oncologic diseases.
Preclinical Evaluation of ALS20, a New and Improved Lentiviral Vector for Beta-Globinopathies
Authors: Laura Breda, Valentina Ghiaccio, Silvia Pires Lourenco, Danuta Jadwiga Jarocha, Yasuhiro Ikawa, Naoto Tanaka, Virginia Guzikowski, Carla Casu, Kim Smith-Whitley, Janet L. Kwiatkowski, Stefano Rivella
Journal: Blood (2019)
Intravenous Ondansetron in Pregnancy and Risk of Congenital Malformations
Authors: Krista F. Huybrechts, Sonia Hernandez-Diaz, Loreen Straub, Kathryn J. Gray, Yanmin Zhu, Helen Mogun, Brian T. Bateman
Journal: JAMA (2019)

This pharmacoepidemiology study uses Medicaid data to estimate associations between first-trimester use of intravenous ondansetron and risk of cardiac malformations and oral cleft in children of exposed mothers.
Composition of Immune Subpopulations Influence Multiple Myeloma Disease Progression
Authors: Rupal Ramakrishnan, Alexandra Achille, Tuan Nyugen, Ian Taylor, Gabriel De Avila, Raghunandanreddy Alugubelli, Mark B. Meads, Ariosto Siqueira Silva, Kenneth H. Shain, Jason B. Brayer
Journal: Blood (2019)
Delivery of long-term-injectable agents for TB by lay carers: pragmatic randomised trial
Authors: Danielle B Cohen, Kuzani Mbendera, Hendramoorthy Maheswaran, Mavuto Mukaka, Helen Mangochi, Linna Phiri, Jason Madan, Geraint Davies, Elizabeth Corbett, Bertel Squire
Journal: Thorax (2019)

Background People with recurrent or drug-resistant TB require long courses of intramuscular injections. We evaluate a novel system in which patient-nominated lay carers were trained to deliver intramuscular injections to patients in their own homes. Methods A pragmatic, individually randomised non-inferiority trial was conducted at two hospitals in Malawi. Adults starting TB retreatment were recruited. Patients randomised to the intervention received home-based care from patient-nominated lay people trained to deliver intramuscular streptomycin. Patients receiving standard care were admitted to hospital for 2 months of streptomycin. The primary outcome was successful treatment (alive and on treatment) at the end of the intervention. Results Of 456 patients screened, 204 participants were randomised. The trial was terminated early due to futility. At the end of the intervention, 97/101 (96.0%) in the hospital arm were still alive and on treatment compared with 96/103 (93.2%) in the home-based arm (risk difference −0.03 (95% CI −0.09 to 0.03); p value 0.538). There were no differences in the proportion completing 8 months of anti-TB treatment; or the proportion experiencing 2-month sputum culture conversion. The mean cost of hospital-based management was US$1546.3 per person, compared to US$729.2 for home-based management. Home-based care reduced risk of catastrophic household costs by 84%. Conclusions Although this trial failed to meet target recruitment, the available data demonstrate that training patient-nominated lay people has potential to provide a feasible solution to the operational challenges associated with delivering long-term-injectable drugs to people with recurrent or drug-resistant TB in resource-limited settings, and substantially reduce costs. Further data under operational conditions are required. Trial registration number ISRCTN05815615 .
Phase I Clinical Trial of CK0801 (cord blood regulatory T cells) in Patients with Bone Marrow Failure Syndrome (BMF) Including Aplastic Anemia, Myelodysplasia and Myelofibrosis
Authors: Tapan M. Kadia, Hongbing Ma, Ke Zeng, Mitsutaka Nishimoto, Mi-Ae Lyu, Meixian Huang, Musa Yilmaz, Courtney D. DiNardo, Ghayas C. Issa, Simrit Parmar, Swami P. Iyer, Parameswaran Hari, Naval G. Daver, Elias Jabbour, Gautam M. Borthakur, Srdan Verstovsek
Journal: Blood (2019)
Maintaining the Cellular Anti-Viral and Anti-Leukemic Activities in GvHD Patients Undergoing Extracorporeal Photophoresis Therapy
Authors: Ruben A. Gößmann, Lei Wang, Ming Ni, Mingya Yang, Thomas Luft, Ute Hegenbart, Stefan O. Schönland, Patrick Wuchter, Volker Eckstein, William Hermann Krüger, Ronit Yerushalmi, Katia Beider, Arnon Nagler, Carsten Müller-Tidow, Peter Dreger, Michael Schmitt, Anita Schmitt
Journal: Blood (2019)
PATH-24. CXCR4 IS A POTENTIAL THERAPEUTIC TARGET FOR GLIOBLASTOMA AND DIFFUSE INTRINSIC PONTINE GLIOMAS
Authors: Soheil Zorofchian, Ping Zhu, Takeshi Takayasu, Adan Rios, Martha Quezado, Yoshua Esquenazi, Leomar Y Ballester
Journal: Neuro-Oncology (2019)

Abstract Glioblastoma (GBM) is the most common adult malignant brain tumor with poor prognosis and Diffuse Intrinsic Pontine Glioma (DIPG) is a pediatric type of glioblastoma for which there is no effective therapy. CXCR4, a G-protein coupled receptor, has been shown to play a role in GBM invasion, cell survival, proliferation and angiogenesis. A CXCR4 inhibitor (AMD3100/Plerixafor) has been suggested as a potential therapeutic strategy for GBM with an isolated case report of a long-term survivor and an ongoing clinical trial evaluating its effects in GBM patients. However, there is a poor understanding of the expression of CXCR4 in GBM and DIPGs. In this study, we evaluated the expression of CXCR4 in 21-DIPG and 36-GBM cases. In GBMs, CXCR4 was expressed in 5.6% of cases in tumor cells and in 19.4% of cases in endothelial cells in blood vessels. In DIPGs, we observed expression of CXCR4 in 28.6% of cases in tumor cells and in 14.3% of cases in endothelial cells. We observed absence of CXCR4 expression in all IDH-mutant GBMs. There was no correlation between CXCR4 or EGFR expression, p53-mutations or H3F3A p.K27M mutations in DIPGs. There was a trend of poorer prognosis in CXCR4 positive DIPGs but the difference did not reach statistical significance. Furthermore, we evaluated the effects of Plerixafor in the survival of DIPG and U87-GBM cell lines and observed a dose-dependent reduction in cell viability. RT-PCR and immunohistochemistry of DIPG cells showed variable CXCR4 expression in the cell lines that did not correlate with sensitivity to Plerixafor. In conclusion, in vitro experiments show that the CXCR4 inhibitor Plerixafor is a potential therapeutic strategy for GBM and DIPGs. However, CXCR4 is not universally expressed in glioblastomas and its expression should be considered in clinical trials that evaluate the efficacy of CXCR4 inhibitors in GBM and DIPGs.
Molecular Treatment Stratification for Newly Diagnosed High-Risk Myeloma, Including Plasma Cell Leukemia - Feasibility Results of the Ukmra Optimum: MUK9 Trial (NCT03188172)
Authors: Matthew Jenner, Amy L Sherborne, Andrew Hall, Vallari Shah, Katrina Walker, Sidra Ellis, Kim Sharp, Amy Price, James Croft, Graham Jackson, Louise Flanagan, Mark T Drayson, Ruth M De Tute, Roger G. Owen, Guy Pratt, Gordon Cook, Sarah R Brown, Martin F. Kaiser
Journal: Blood (2019)
World-wide Prevalence of Substitutions in HCV Genome Associated With Resistance to Direct-Acting Antiviral Agents
Authors: Zhenqiu Liu, Xianhua Mao, Jiaqi Wu, Kangkang Yu, Qin Yang, Chen Suo, Ming Lu, Li Jin, Tiejun Zhang, Xingdong Chen
Journal: Clinical Gastroenterology and Hepatology (2019)
Sexism at the BMA: the ordinary BMA doctor has moved forward
Authors: Helena M McKeown
Journal: BMJ (2019)

It is unfortunate that in her otherwise depressingly accurate editorial Jane Dacre unwittingly misrepresented the leadership of the BMA.1 This gives me the chance to clarify the evolution of our democratic leadership—which tells a more positive narrative but is perhaps less exciting than the incorrect headline that we have never had a female chair. …
NIMG-57. SERIAL HYPERPOLARIZED 13C PYRUVATE AND 1H METABOLIC IMAGING IN RECURRENT HIGH-GRADE GLIOMA
Authors: Javier Villanueva-Meyer, Adam Autry, Jeremy Gordon, Hsin-Yu Chen, Marisa Lafontaine, Susan Chang, Duan Xu, Peder Larson, Daniel Vigneron, Yan Li
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION Hyperpolarized (HP) 13C MRI is a novel metabolic imaging that allows for real time in vivo probing of pathway-specific metabolic processes relevant to gliomas. The first human brain application reports were published recently. In this study, we characterized longitudinal dynamic and static brain metabolism changes from serial HP 13C and 1H metabolic imaging in a patient with multiply recurrent glioma. METHODS Eight dynamic HP 13C imaging, 1H MRI and MRSI examinations were acquired over a period of 15 months in a patient with multiply recurrent glioma that underwent malignant transformation. The patient was imaged after initial tumor debulking, after chemoradiotherapy, at first recurrence, after re-irradiation and anti-angiogentic therapy, and at second recurrence. Ratios of pyruvate-to-lactate and pyruvate-to-bicarbonate were calculated from HP 13C imaging and choline-to-NAA index (CNI) was derived from 1H MRSI. RESULTS/ DISCUSSION Successful therapies are usually associated with a drop in pyruvate-to-lactate conversion, mediated by different mechanisms from various treatments. We identified three key findings over repeat HP 13C MRIs: 1) a marked response to therapy with a reduction in pyruvate-to-lactate conversion corresponding to associated imaging response to therapy at the primary site of disease. Following chemoradiotherapy, the volume of T2 hyperintensity decreased from 28.21cc to 15.29 cc, and the volume of metabolic abnormality (CNI &gt;3) decreased from 27.84 cc to 10.36 cc. 2) increasing pyruvate-to-lactate conversion in a region of recurrence before morphologic signal abnormality, and 3) a reduction in pyruvate-to-lactate conversion in a recurrent lesion following anti-angiogenic therapy. CONCLUSION Here we show that one can reliably image glioma patients using HP 13C MRI alongside standard of care morphologic and physiologic MRI including diffusion, perfusion, and 1H MRSI. Serial HP 13C MRI can be performed in the neuro-oncologic clinical setting and pyruvate-to-lactate metabolism may be useful to monitor treatment response.
A Regional Massive Hemorrhage Protocol: Designed with a Modified Delphi Technique to Obtain Consensus
Authors: Jeannie Callum, Calvin Yeh, Mark McVey, Andrew Petrosoniak, Stephanie Cope, Troy Thompson, Victoria Chin, Keyvan Karkouti, Avery Nathans, Kimmo Murto, Suzanne Beno, Jacob Pendergrast, Andrew McDonald, Neil Adhikari, Asim Alam, Donald M. Arnold, Lee Barratt, Andrew Beckett, Sue Brenneman, Hina Chaudhry, Allison Collins, Margaret Harvey, Jacinthe Lampron, Russell MacDonald, Clarita Margarido, Amanda McFarlan, Barto Nascimento, Wendy Owens, Menaka Pai, Sandro Rizoli, Theodora Ruijs, Robert Skeate, Teresa Skelton, Michelle Sholzberg, Kelly Syer, Jami-Lynn Viveiros, Josee Theriault, Alan T. Tinmouth, Rardi Van Heest, Susan White, Michelle P. Zeller, Katerina Pavenski
Journal: Blood (2019)
Trends in Autologous Transplantation for Myeloma in EBMT Centres between 1993 and 2017
Authors: Patrick J Hayden, Dirk-Jan Eikema, Linda Koster, Hartmut Goldschmidt, Didier Blaise, Michael Potter, Cyrille Touzeau, Anne Huynh, Jenny Byrne, Cyrille Hulin, Neil K Rabin, Reuben Benjamin, Jan J Cornelissen, Hareth Nahi, Gordon Cook, John G. Gribben, Ellen Meijer, Péter Reményi, Jiri Mayer, Panagiotis Tsirigotis, Paolo Bernardeschi, Meral Beksac, Stefan O. Schönland, Ibrahim Yakoub-Agha
Journal: Blood (2019)
Incidence, Diagnosis, and Outcome of Acquired Thrombotic Thrombocytopenic Purpura (aTTP): A Nationwide Survey By the Spanish Apheresis Group
Authors: Maria Cristina Pascual Izquierdo, Julio Del Rio-Garma, Javier De La Rubia, Aurora Viejo, Jesus Fernandez-Sojo, Jesus Martin, Xavier Solanich, Faustino García-Candel, Luis Hernandez, Marta Fernandez, Ana Oliva, Jose Maria Garcia-Gala, Maria Eva Mingot-Castellano, Ines Gomez-Seguí, Rosa Goterris, Michael Calviño, María Luisa Antelo, Sol Sanchez, Jose Antonio Moreno, Cristina Amunarriz, Jose Garcia-Arroba, Carmen Fernandez, Nieves Alonso, Victoria Gonzalez, Luisa Guerra, M. Elena Moreno, Moreno M. Dolores, Gemma Moreno, Melisa Daorta, Esther Chica, Rafael Del Orbe, Joan Cid, Margarita Berberana, Carmen Ballester, Sara Nistal Gil, Julia Vidan, Maite Calderon, Consuelo Martinez Redondo, Jose Carlos Hernandez, Marina Gordillo, Angel Salgado, Ramon Salinas
Journal: Blood (2019)
Targeting DHODH with AG-636 Induces Apoptosis and Differentiation and Inhibits Mitochondrial Function in AML, Translating into Anti-Tumor Efficacy in Vitro and in Vivo
Authors: Zhihong Zeng, Natalia Baran, Sergej Konoplev, Antonio Cavazos, Qi Zhang, Vinitha Mary Kuruvilla, Philip Lorenzi, Hagop M. Kantarjian, Michael Andreeff, Courtney D. DiNardo, Joshua Murtie, Danielle Ulanet, Marina Y Konopleva
Journal: Blood (2019)
Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) - 15-Month Safety, Response and MRD Evaluation: Third Interim Analysis from the Phase II Vision HO141 Trial
Authors: Carsten Utoft Niemann, Julie Dubois, Sabina Kersting, Lisbeth Enggaard, Gerrit J Veldhuis, Rogier Mous, Clemens Mellink, Johan A Dobber, Christian Bjørn Poulsen, Henrik Frederiksen, Ann Janssens, Ida Schjødt, Ellen C Dompeling, Juha Ranti, Mattias Mattsson, Mar Bellido, Hoa T Tran, Kazem Nasserinejad, Mark-David Levin, Arnon P. Kater
Journal: Blood (2019)
Rising opioid prescriptions may not be a crisis
Authors: Lukas Radbruch
Journal: BMJ (2019)

Smith and colleagues describe widespread opioid prescribing and use in European and North American countries.1 The editorial, however, neglects some important factors, such as the contribution of illicit opioids, that play a major role in the US opioid crisis.

The authors do not mention other literature highlighting the lack of an opioid crisis in Europe.2 They …
Coagulation mixing studies: Utility, algorithmic strategies and limitations for lupus anticoagulant testing or follow up of abnormal coagulation tests
Authors: Emmanuel J. Favaloro
Journal: American Journal of Hematology (2019)

Coagulation testing underpins the investigation of hemostasis and/or monitoring of anticoagulation therapy for prevention and/or treatment of thrombosis related pathology. Assessment of coagulation results requires comparison against a normal reference range or interval (NRR/NRI). Results flagged as "abnormal" (ie, above the NRR/NRI for patients not on anticoagulant therapy), typically require further evaluation. eg, follow up or reflexive testing is used to identify the reason for prolongation, especially when supported by clinical context (eg, bleeding). Mixing tests may have utility to help identify the pathway of follow-up testing (ie, towards investigation of factor deficiencies, or else inhibitors), and are also useful for investigation of lupus anticoagulants (LA). In general, mixing tests that "correct" tend to suggest the presence of factor deficiencies, where as those that do not correct suggest the presence of "inhibitors". Various approaches can be used to identify correction/non-correction, and all have strengths and limitations. Furthermore, eventual identification of causal factor deficiencies or even "inhibitors" may (eg, factor VIII or IX deficiencies or inhibitors) or may not (eg, factor XII deficiency) be clinically important. Ultimately, mixing studies performed in view of appropriate clinical scenarios (eg, bleeding patient) and for LA investigations in symptomatic patients will have best utility.
Combination of Venetoclax and Ibrutinib Increases bcl2-Dependent Apoptotic Priming, Reduces ITK-Phosphorylation and Is Clinically Promising in Relapsed/Refractory T-Prolymphocytic Leukemia
Authors: Christoph Kornauth, Charles Herbaux, Bernd Boidol, Chantal Guillemette, Patrick Caron, Stéphanie Poulain, Olivier Tournilhac, Marius E Mayerhoefer, Ulrich Jaeger, Stefan Kubicek, Matthew S. Davids, Philipp Bernhard Staber
Journal: Blood (2019)
Upregulation of smooth muscle Rho-kinase protein expression in human asthma
Authors: Lu Wang, Pasquale Chitano, Peter D. Paré, Chun Y. Seow
Journal: European Respiratory Journal (2019)

<b>An important phenotypic change is associated with human asthma: the protein expression of both isoforms of Rho-kinase, ROCK1 and ROCK2, is increased in the smooth muscles of intra-parenchymal airways and in the pulmonary blood vessels</b>http://bit.ly/2pPfyxH
Characteristics of Patients with Relapsed/Refractory Burkitt Non-Hodgkin Lymphoma (NHL): Impact on the Feasibility of CAR-T Cell Therapy
Authors: Sonia Fortin Gamero, Yi Lin, Saad S. Kenderian, N. Nora Bennani, Gita Thanarajasingam, Thomas M. Habermann, Grzegorz Nowakowski, Thomas E. Witzig
Journal: Blood (2019)
Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia and Karnofsky Performance Status Score Equal or Lower Than 80%. a Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)
Authors: Francesco Saraceni, Myriam Labopin, Edouard Forcade, Nicolaus Kröger, Gerard Socie, Riitta Niittyvuopio, Jan J Cornelissen, Hélène Labussière-Wallet, Didier Blaise, Goda Choi, Jenny Byrne, Gaëlle Guillerm, Thierry Lamy, Jordi Esteve, Ali Bazarbachi, Bipin N. Savani, Arnon Nagler, Mohamad Mohty
Journal: Blood (2019)